Rofo and colleagues successfully introduced soluble NEP into the brain parenchyma of an AD mouse model using a transferrin receptor antibody conjugate construct and showed that the soluble NEP preferentially degrades Aβ monomer (Rofo et al., 2022). The gene discussed is TFRC; the disease is Alzheimer disease.